46 results about "Endothelin Antagonists" patented technology

A compound of the formula (I):or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.

The present invention relates, in general to treatment of pain comprising administering an alpha-2 adrenergic agonist and an endothelin antagonist, wherein administration of the agents acts as an analgesic and ameliorates pain in a subject.

A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells including those originating in the brain and / or nervous system and / or the meninges and / or reactive neuroglia cells and / or primitive neuroectodermal tumor cells and / or on Kaposi sarcoma is provided. Furthermore, a method for reducing degenerate GnRH-positive tumor cells and / or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and / or GnRH antagonist and / or an erythropoietin agonist, and / or a thrombopoietin agonist, and / or a endothelin antagonist and / or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.

The invention discloses skin whitening and freckle removing composition and an application thereof. The composition comprises forchlorfenuron and a whitening agent, wherein the whitening agent adoptsa tyrosinase activity inhibitor, a tyrosinase saccharification inhibitor, a tyrosinase decomposition agent, a melanocyte toxicity agent, a melanin transport blocking agent, a sunscreen agent, a reducing agent, a chemical stripping agent and an endothelin antagonist or a free radical scavenger. The composition can remove wrinkles and freckles, prevent water loss and keep skin moist, and has the functions of whitening the skin, removing freckles and wrinkles, preserving moisture and the like. Compared with the prior art, the composition is safe to use, simple and convenient to manufacture and suitable for industrial mass production.

Methods of treating diabetic ketoacidosis are disclosed. The methods utilize an endothelin antagonist to treat diabetic ketoacidosis in mammals, including humans.

A method for recognizing and evaluating the presence and function of GnRH receptors on tumor cells including those originating in the brain and / or nervous system and / or the meninges and / or reactive neuroglia cells and / or primitive neuroectodermal tumor cells and / or on Kaposi sarcoma is provided. Furthermore, a method for reducing degenerate GnRH-positive tumor cells and / or for decreasing cellular replication of the above GnRH-positive tumor cells comprising administering to a cell or to a subject a replication decreasing amount of a GnRH agonist and / or GnRH antagonist and / or an erythropoietin agonist, and / or a thrombopoietin agonist, and / or a endothelin antagonist and / or a gonadotropin inhibiting hormone agonist is also provided. Furthermore, a diagnostic kit for detecting GnRH receptors on tumor cells according to the present methods is disclosed.

A composition and method of treating fever, and optionally treating pain, is disclosed. The composition and method utilize a nonopioid analgesic and an endothelin antagonist as active agents to treat fever in mammals, including humans. The composition also is useful in the prevention and treatment of stroke and other cardiovascular disorders, like myocardial infarction.

The invention describes novel nitrosated and / or nitrosylated cardiovascular compounds or pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and / or nitrosylated cardiovascular compound, and, optionally, at least one nitric oxide donor and / or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one cardiovascular compound of the invention, that is optionally nitrosated and / or nitrosylated, and, optionally, at least one nitric oxide donor compound and / or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c) treating diabetes; (d) treating diseases resulting from oxidative stress; (e) treating endothelial dysfunctions; (f) treating diseases caused by endothelial dysfunctions; (g) treating cirrhosis; (h) treating pre-eclampsia; (j) treating osteoporosis; and (k) treating nephropathy. The nitrosated and / or nitrosylated cardiovascular compounds are preferably nitrosated and / or nitrosylated aldosterone antagonists, nitrosated and / or nitrosylated angiotensin II antagonists, nitrosated and / or nitrosylated calcium channel blockers, nitrosated and / or nitrosylated endothelin antagonists, nitrosated and / or nitrosylated hydralazine compounds, nitrosated and / or nitrosylated neutral endopeptidase inhibitors and nitrosated and / or nitrosylated renin inhibitors.

The invention provides a skin care spray with skin-whitening, spot-fading, and acne-removing functions. The skin care spray is mainly composed of following components in percentage by weight: 2 to 6%of vitamin C, 5 to 8% of pearl powder, 4 to 10% of plant extract, 10 to 30% of aloe, 3 to 10% of endothelin antagonist, 0.05 to 2% of hyaluronic acid, 0.5 to 1.5% of salicylic acid, 5 to 10% of lavender essential oil, 20 to 35% of deionized water, and 20 to 30% of skincare product auxiliary matrix. The skin care spray is mild and nonirritant, is suitable for various skins, has skin-whitening, spot-fading, and acne-removing functions, and makes skin become smooth, lustrous and elastic for a long term.

The invention provides a phenoxy phenylacetic acid endothelin antagonist shown in a formula (I) or a pharmaceutically acceptable salt thereof, and also provides a preparation method of the benzene oxygen phenylacetic acid endothelin antagonist or the pharmaceutically acceptable salt thereof, and an application thereof in preparation of a medicament for treating cardiovascular and cerebrovascular diseases, tumors, diabetes mellitus, nephrosis, asthma or hyperthyroidism.

The invention provides methods of treating and / or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme inhibitor, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin inhibitor, and optionally at least one compound used to treat cardiovascular diseases and / or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and / or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and / or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress.